1. 607TiPBIG BANG study: A multicenter phase II study of the MEK inhibitor binimetinib + BRAF inhibitor encorafenib + anti-EGFR antibody cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer (EPOC 1703). (23rd October 2018) Authors: Kotani, D; Bando, H; Masuishi, T; Komatsu, Y; Yamaguchi, K; Nakajima, T E; Satoh, T; Nishina, T; Esaki, T; Nomura, S; Sakamoto, S; Iida, S; Matsuda, S; Yonemura, M; Fuse, N; Sato, A; Fujii, S; Ebi, H; Ohtsu, A; Yoshino, T Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 608TiPBRAVERY study: A multicenter phase II study of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer (EPOC1701). (23rd October 2018) Authors: Masuishi, T; Taniguchi, H; Kotani, D; Bando, H; Komatsu, Y; Yamaguchi, K; Nakajima, T E; Satoh, T; Nishina, T; Esaki, T; Wakabayashi, M; Nomura, S; Sakamoto, S; Ono, H; Hirano, N; Fujishiro, N; Fuse, N; Sato, A; Ohtsu, A; Yoshino, T Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗